CrowdStrike In Strong Position For Cyber-Security Consolidation, Says RBC Analyst

RBC Capital Markets analyst Matthew Hedberg reiterated an Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:CRWD), raising the price target to $180 from…
  • RBC Capital Markets analyst Matthew Hedberg reiterated an Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:CRWD), raising the price target to $180 from $170.
  • The company will report its fiscal first quarter of 2024 on Wednesday, May 31, 2023.
  • The analyst expects ARR/customer to continue to trend higher (although customer count is now an annual disclosure), larger initial deal sizes, cross-sell momentum, and a record pipeline exiting the quarter.
  • The analyst sees slight outperformance in Q1 results and a slight upside to FY24 guidance that likely works higher through the year.
  • Hedberg thinks that CrowdStrike is in a good position to consolidate customer spend as the big gets bigger with cyber-security. 
  • The company’s TAM of $36.5 billion is expected to expand to $43.6 billion by the year-end.
  • The analyst notes that further upside scenarios of the company include a combination of higher cross-selling, better new customer additions, and a stable-to-better macro environment.
  • However, given the crowded nature of the market, potential pricing pressure can be a headwind going ahead. 
  • Based on the above, the analyst sees Q1 EPS at $0.51, with revenues of $676 million.
  • Price Target: CRWD shares are trading higher by 1.99% to $157.18 on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Earlier PEARL Phase III Trial of Imfinzi Monotherapy in Stage IV Non-small Cell Lung Cancer Did Not Achieve Statistical Significance for the Primary Endpoints

The PEARL Phase III trial for AstraZeneca's Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoints of improving overall survival (OS) versus platinum-based chemotherapy as a monotherapy treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC) whose tumour cells express high levels (25% or more) of PD-L1, or in a subgroup of patients at lo

AZN